A Swedish database of over 35,000 individuals found better cardiovascular outcomes when ezetimibe was added earlier to statin therapy for secondary prevention. Study authors deemed ezetimibe a ...

Please provide your email address to receive an email when new articles are posted on . It is well known that HMG-CoA reductase inhibitors reduce LDL, a surrogate marker in atherosclerotic disease, as ...

May 19, 2011 (Charlottesville, Virginia) — Whereas statins appeared to halt atherosclerosis, ezetimibe (Zetia, Merck/Schering-Plough) was associated with an increase in plaque volume in peripheral ...

Both statin and ezetimibe are commonly prescribed medicines to manage high cholesterol levels. Read on as a doctor explains which one is better for you.

In this study, after a six- to eight-week washout period, patients with mixed hyperlipidemiaLDL cholesterol between 130 and 220 mg/dL (between 100 and 180 mg/dL for type 2 diabetics) and triglycerides ...

Ezetimibe is a lipid-lowering agent, prescribed for hypercholesterolemia. Cholestyramine can cause a decrease in the absorption of Ezetimibe resulting in a reduced serum concentration and potentially ...

Ezetimibe is a nonstatin low-density lipoprotein cholesterol-lowering small molecule drug. Ezetimibe is the only currently FDA-approved approved member of the of intestinal cholesterol reuptake ...

What to do: If your bottle of ezetimibe 10 mg tablets contains any perindopril 4 mg tablets, or if you are unsure, return it to your pharmacy immediately. If you are unable to return your tablets to ...

A recent simulation study published in the journal Scientific Reports analyzed representative data of over two million outpatients in Germany, in which the researchers reported that a combination of ...

The FDA has approved a new combination drug from Merck for lowering cholesterol. The drug, which will carry the brand name of Liptruzet, is a combination of two previously approved ...

The US Food and Drug Administration has declined to extend the indication for the cholesterol-lowering drug ezetimibe to include cardiovascular event reduction, the manufacturer has announced. Merck ...

(HealthDay)—Treatment with the lipid-lowering therapy ezetimibe/simvastatin is not associated with an increased risk of developing cancer or an increased risk of dying from cancer, according to ...